newsfilter
← Latest News
GlobeNewswire·

Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $26.2 Million from the Core Commercial Business, a 32% Increase Over First Quarter 2022 -- Company Reiterates Full-Year Revenue Guidance of $143 to $158